Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce NDA Submission of CloniBID to Treat Hypertension

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) and Addrenex Pharmaceuticals, Inc. today announced that Addrenex has submitted a 505(b)(2) New Drug Application (NDA) to the Federal Food & Drug Administration (FDA) for CloniBID for the treatment of hypertension. Upon FDA approval, Sciele expects to launch this product in the first half of 2009.

Back to news